Previous 10 | Next 10 |
2023-05-12 07:31:54 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q1 GAAP EPS of -$0.41. Revenue of $0.76M. As of March 31, 2023, Sol-Gel had $20.3 million in cash, cash equivalents and deposits, and $18.4 million in marketable securities for a total balance ...
Positive trends continue for TWYNEO ® and EPSOLAY ® with recurrent prescriber base s at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) fo...
2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% . Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune &...
2023-03-10 07:39:20 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): FY GAAP EPS of -$0.65 misses by $0.15 . Revenue of $3.88M (-87.6% Y/Y) misses by $1.8M . As of December 31, 2022, Sol-Gel had $24.9million in cash, cash equival...
Recent acquisition of Phase 3-ready SGT-610 ( p atidegib ) , an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome A Phase 3 study of SGT-610...
Sol-Gel Technologies ( NASDAQ: SLGL ) said it is acquiring topically-applied drug patidegib from PellePharm, and separately announced $22.8M registered direct and private placement offerings. Sol-Gel will pay PellePharm $4.7M upfront and total development and NDA acceptance miles...
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY ® and TWYNEO ® , two innovative dermatology products that were launched ...
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA Phase 3 study expected to initiate in the second half of 2023, with results expected b...
Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q3 GAAP EPS of -$0.15 misses by $0.08 . Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M . As of September 30, 2022, Sol-Gel had $25.5 million in cash, cash equivalents and deposits, and $9.8 million in marketa...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...